Lenz Therapeutics Announces FDA Approval of Vizz for the Treatment of Presbyopia
Near vision improvements were demonstrated within 30 minutes and lasted up to 10 hours in clinical trials.
Clinical Scorecard: FDA Approval of Vizz (aceclidine ophthalmic solution) 1.44% for Presbyopia
At a Glance
| Category | Detail |
|---|
| Condition | Presbyopia |
| Key Mechanisms | Contracts iris sphincter muscle causing a pinhole effect with sub-2 mm pupil to extend depth of focus and improve near vision without myopic shift |
| Target Population | Adults with presbyopia |
| Care Setting | Outpatient ophthalmic treatment |
Key Highlights
- Near vision improvements observed within 30 minutes of dosing
- Effect lasts up to 10 hours after a single dose
- Safety and efficacy confirmed in CLARITY 1, 2, and 3 clinical trials with once-daily dosing
Guideline-Based Recommendations
Diagnosis
- Diagnosis of presbyopia based on clinical assessment of near vision impairment in adults
Management
- Once-daily administration of Vizz (aceclidine ophthalmic solution) 1.44% eye drops
Monitoring & Follow-up
- Monitor for common adverse events such as instillation site irritation, dim vision, and headache
- Assess near vision improvement and tolerability during treatment
Risks
- Mild, transient, and self-resolving adverse events including instillation site irritation, dim vision, and headache
Patient & Prescribing Data
Adults with presbyopia enrolled in clinical trials (CLARITY 1, 2, and 3)
Once-daily dosing for up to 6 months demonstrated sustained near vision improvement and favorable safety profile
Clinical Best Practices
- Administer Vizz once daily to achieve near vision improvement lasting up to 10 hours
- Educate patients about potential mild and transient side effects
- Evaluate patient response within 30 minutes post-dose to confirm efficacy
- Consider long-term safety data from 6-month clinical trial when planning treatment duration
References
